Sign in

LTGO on Nasdaq

Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. is an American pharmaceutical preparations company based in Thousand Oaks.1 Its shares trade on Nasdaq under the symbol LTGO.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerLTGO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersThousand Oaks, California1
  • Incorporated inDE2
  • Business address1300 Rancho Conejo Blvd., Suite 305, Thousand Oaks, Ca2
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Fiscal year2025
Dividend per share$0.003

Compare Latigo Biotherapeutics, Inc. with another company

Corporate structure

Latigo Biotherapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Latigo Biotherapeutics, Inc.

  • Latigo Biotherapeutics, Inc. Thousand Oaks, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Latigo Biotherapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nima Farzan2026–now

President

  1. Nima Farzan2026–now

Chief financial officer

  1. Neha Krishnamohan2026–now
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerTim Lugo named Feb 13, 202511
  • DirectorDeborah Palestrant named Feb 13, 202511
  • DirectorJim Tananbaum named Feb 13, 202511
  • DirectorNancy Stagliano named Feb 13, 202511

Timeline

  1. Sep 3, 20268-K Results of operations12
  2. Aug 10, 20268-K Bylaws or fiscal year changed; Other events13
  3. Aug 6, 2026New chief executive Nima Farzan becomes CEO4

Calendar

Coming up

  1. Dec 3, 2026Reports results for the quarter ending Sep/202614

When it reported results

  1. Sep 3, 2026Reported quarterly or annual results12

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

40 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 20 insider forms, 4 large holders, 1 private raises, 12 other. The latest 20:

  1. Sep 3, 202610-Q EDGAR
  2. Sep 3, 20268-K EDGAR
  3. Aug 18, 2026SCHEDULE 13G EDGAR
  4. Aug 17, 2026SCHEDULE 13G EDGAR
  5. Aug 17, 2026SCHEDULE 13D EDGAR
  6. Aug 13, 2026SCHEDULE 13G EDGAR
  7. Aug 12, 20264 EDGAR
  8. Aug 12, 20264 EDGAR
  9. Aug 12, 20263 EDGAR
  10. Aug 11, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Aug 10, 20264 EDGAR
  12. Aug 10, 20264 EDGAR
  13. Aug 10, 2026S-8 EDGAR
  14. Aug 10, 20268-K EDGAR
  15. Aug 10, 20264 EDGAR
  16. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Aug 7, 2026424B4 EDGAR
  18. Aug 6, 2026EFFECT EDGAR
  19. Aug 6, 20263 EDGAR
  20. Aug 6, 20263 EDGAR

The 40 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 10, 2026Tananbaum James B.DirectorBuy140,000$18.00$2.5MForm 4
Aug 10, 2026Foresite Capital Fund VI LP10% ownerBuy140,000$18.00$2.5MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 28, 2025Raised $50 million in a private offering of equity Form D: $150 million offered in all Form D

SEC filer profile

How Latigo Biotherapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLatigo Biotherapeutics, Inc.1
  • CIK0002056611
  • Employer ID (EIN)83-26258381
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1300 Rancho Conejo Blvd., Suite 305, Thousand Oaks, CA1
  • Phone805-716-29271
  • Shares outstanding66,299,347 as of Sep 1, 20263
  • On EDGAR sinceFeb 13, 20251
  • Filings40 in all: 3 (13), 4 (7), SCHEDULE 13G (3), 8-K (2), DRS/A (2), S-1/A (2), 10-Q (1), 424B4 (1)1
    All 17 form types

    8-A12B (1), CERT (1), D (1), DRS (1), EFFECT (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13D (1)

  • Latest filingsQuarterly report (10-Q) Sep 3, 2026
    Latest 8-K (8-K) Sep 3, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18